16 Oct 2007 -
NicOx S.A. announced the opening of its United States headquarters in Warren, New Jersey, where the Company will base its Commercial Affairs and U.S. Clinical Operations departments. Mr. Sanjiv Sharma, who was appointed last April as Vice President of Commercial Affairs, will head the U.S. Office. In addition to commercial activities, U.S. Clinical Operations will be based in this office, led by Joan Sutphen, who joined NicOx in February 2007 as Director of U.S. Clinical Operations.
"As NicOx transitions from a pure research and development organization to a fully integrated commercial company, we recognized the need to open NicOx' U.S. headquarters. As we move closer to our anticipated New Drug Application filing for naproxcinod, we will need to build our sales and marketing infrastructure," stated Damian Marron, Vice President of Corporate Development at NicOx. "Over the past few months, Sanjiv has built an excellent U.S.-based team, which has begun to develop commercial strategies for our product portfolio. In addition, Sanjiv's team will provide indispensable support to our management team, particularly relating to new in-licensing and acquisitions opportunities."
NicOx has made additional appointments to the Commercial Affairs team, all of whom have marketing, market research, and business analysis experience. The NicOx' US clinical team will establish a permanent clinical presence in the US where the majority of NicOx' clinical trials are planned and conducted and will help to implement NicOx' US clinical strategy and provide strong support and management of the Clinical Research Organizations (CRO) working for the Company. The 6,000 square feet facility will accommodate additional hires in the coming months, as the Company prepares for the filing of a New Drug Application (NDA) for naproxcinod, NicOx' first in class COX-inhibiting Nitric Oxide Donator (CINOD) for the treatment of the signs and symptoms of osteoarthritis.
Top
Contact
Print version
PDF version
Send article
RSS-Feed